174 related articles for article (PubMed ID: 23460040)
1. Two innovative pharmaceutical forms of leuprorelin: results from 818 patients with advanced prostate cancer.
Gravel P; Samland D; Löffler M; Maier S; Panozzo M; Muenzberg M
Adv Ther; 2013 Mar; 30(3):271-85. PubMed ID: 23460040
[TBL] [Abstract][Full Text] [Related]
2. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M
Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697
[TBL] [Abstract][Full Text] [Related]
3. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
4. Is high-dose leuprorelin acetate effective and safe in asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial.
Lee SH; Lee HM; Kim SW; Lee ES; Hong SJ; Kim CS; Kang TW; Chung BH
Yonsei Med J; 2014 Mar; 55(2):310-5. PubMed ID: 24532497
[TBL] [Abstract][Full Text] [Related]
5. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
Berges R; Bello U
Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study.
Schmitz-Dräger BJ; Mühlich S; Lange C; Benderska-Söder N; Bismarck E; Starlinger R; Ottillinger B; Hakenberg OW
Urol Int; 2021; 105(5-6):436-445. PubMed ID: 33631760
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic-pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin.
Snelder N; Drenth HJ; Riber Bergmann K; Wood ND; Hibberd M; Scott G
Br J Clin Pharmacol; 2019 Jun; 85(6):1247-1259. PubMed ID: 30731514
[TBL] [Abstract][Full Text] [Related]
8. Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.
Merseburger AS; Björk T; Whitehouse J; Meani D
J Comp Eff Res; 2015 Sep; 4(5):447-53. PubMed ID: 25521079
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of two innovative pharmaceutical forms of leuprorelin acetate.
Geiges G; Schapperer E; Thyroff-Friesinger U; Engert ZV; Gravel P
Ther Adv Urol; 2013 Feb; 5(1):3-10. PubMed ID: 23372606
[TBL] [Abstract][Full Text] [Related]
10. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
Khan MS; O'Brien A
Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
[TBL] [Abstract][Full Text] [Related]
12. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
[TBL] [Abstract][Full Text] [Related]
13. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
14. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan.
Suzuki K; Namiki M; Fujimoto T; Takabayashi N; Kudou K; Akaza H
Jpn J Clin Oncol; 2015 Dec; 45(12):1168-74. PubMed ID: 26486824
[TBL] [Abstract][Full Text] [Related]
16. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients.
Tunn UW
BMC Urol; 2011 Jul; 11():15. PubMed ID: 21801354
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.
Spitz A; Young JM; Larsen L; Mattia-Goldberg C; Donnelly J; Chwalisz K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):93-9. PubMed ID: 22025196
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Tolerability of Leuprorelin Acetate (Eligard®) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer.
Ohlmann CH; Gross-Langenhoff M
Urol Int; 2018; 100(1):66-71. PubMed ID: 29197875
[TBL] [Abstract][Full Text] [Related]
19. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
20. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer.
Wechsel HW; Zerbib M; Pagano F; Coptcoat MJ
Eur Urol; 1996; 30 Suppl 1():7-14; discussion 19-21. PubMed ID: 8977984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
